A Randomized, Double Blind, Placebo Controlled, Clinical Study to Examine the Benefits of an Oral Product in Panelists With Menopausal Symptoms Including Vasomotor Symptoms (VMS).

Launched by OLLY, PBC · Jun 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a new oral dietary supplement can help women who are experiencing menopausal symptoms, especially frequent hot flashes. The goal is to see if this product can reduce these symptoms and improve overall comfort during menopause. The study will compare the effects of the supplement to a placebo, which is a harmless pill with no active ingredients, to understand if the supplement truly makes a difference.

Women between the ages of 40 and 65 who are generally healthy and have been having more than five hot flashes a day for at least two months may be eligible to join. Participants should have changes in their menstrual cycle length and a body weight within a normal range. During the study, women will be asked to keep daily diaries about their symptoms and complete questionnaires to track any changes. The study is carefully designed to ensure participants understand the process and can attend scheduled visits. It’s important to note that women who are pregnant, breastfeeding, on hormone therapy, or have certain health conditions will not be eligible. This trial is not yet recruiting, but it aims to provide helpful information for women looking for safe ways to manage menopausal symptoms.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Healthy Females aged 40 to 65 years
• • Self-reporting menopausal symptoms (\> 5 hot flashes per day) and have been present for a minimum of previous 60 days prior to baseline visit
• • Reporting a variable cycle length of \> 7 days different from normal
• • NORMAL BMI (per metropolitan life tables): under 30 kg/m2
• • Able to read, understand, and complete the study questionnaire and records.
• • Able to understand the study procedures.
• • Able to comply with all study requirements.
• • Written informed consent to participate in the study.
• • Willingness to actively participate in the study and to come to the scheduled visits.
• Exclusion Criteria:
• • Pregnancy or breastfeeding.
• • Immune insufficiency
• • Women of childbearing potential including those still having a menstrual cycle on a regular basis who are not perimenopausal, menopausal or post-menopausal.
• • History of hysterectomy
• • Women on hormone replacement therapy
• • Use of systemic corticosteroids or immunosuppressant drugs.
• • Other diseases or medications that might directly interfere in the study or put the panelist's health under risk, such as: thyroid disease, diabetes mellitus, history of hormone dependent (gynecological) cancer, endometrial hyperplasia, uterine cancer, endometrial cancer, drug and alcohol abuse, mental disorder, abnormality in renal and liver functions, personal or family history of breast cancer in a first degree relative, and history of clotting disorder such as deep vein thrombosis.)
• • Cardiovascular, chronic liver, thyroid or kidney diseases; a history of cancer; a disease or condition that could influence the participants' ability to follow the study protocol
• • Alcohol or drug abuse
• • Use of hormonal contraceptives within the last 3 months
• • Use of other menopause supplements or drugs
• • Uncontrolled hypertension (160/100 mmHg or higher, measured after 10 min of seated rest)
• • Oophorectomy or amenorrhea \> two years.
• • Participating in a different clinical trial within one month of the start of this clinical trial or planning to participate in another clinical trial during the trial period
• • Continuous intake of foods based on Cynanchum wilfordii Hemsley, Phlomis umbrosa Turczaninow, and Angelica gigas Nakai within the past month
• • Employees of the institute or the brand owner or the manufacturers of the product
• • Note: Habitual medicine and supplement intake will be registered prior to inclusion in the study